Stephens assumed coverage on shares of PROCEPT BioRobotics (NASDAQ:PRCT - Free Report) in a report published on Wednesday, Marketbeat.com reports. The brokerage issued an overweight rating and a $70.00 target price on the stock.
A number of other equities analysts also recently commented on PRCT. Bank of America cut their price objective on PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating on the stock in a report on Friday, April 25th. Wall Street Zen upgraded PROCEPT BioRobotics from a "sell" rating to a "hold" rating in a report on Saturday, May 24th. Truist Financial dropped their target price on PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating on the stock in a report on Friday, April 11th. Finally, Oppenheimer started coverage on PROCEPT BioRobotics in a report on Monday. They set a "market perform" rating on the stock. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $87.50.
View Our Latest Stock Analysis on PROCEPT BioRobotics
PROCEPT BioRobotics Trading Up 1.3%
Shares of PROCEPT BioRobotics stock traded up $0.78 during trading hours on Wednesday, reaching $59.24. The stock had a trading volume of 163,415 shares, compared to its average volume of 843,094. The firm has a 50 day simple moving average of $58.14 and a two-hundred day simple moving average of $63.23. The firm has a market capitalization of $3.28 billion, a price-to-earnings ratio of -34.79 and a beta of 1.07. The company has a current ratio of 8.95, a quick ratio of 7.75 and a debt-to-equity ratio of 0.13. PROCEPT BioRobotics has a 1 year low of $47.04 and a 1 year high of $103.81.
PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.04. The company had revenue of $69.16 million for the quarter, compared to the consensus estimate of $65.39 million. PROCEPT BioRobotics had a negative return on equity of 28.09% and a negative net margin of 36.20%. The company's quarterly revenue was up 55.5% compared to the same quarter last year. During the same period last year, the business posted ($0.51) EPS. As a group, equities research analysts anticipate that PROCEPT BioRobotics will post -1.75 earnings per share for the current year.
Insiders Place Their Bets
In other PROCEPT BioRobotics news, Director Antal Rohit Desai sold 25,000 shares of the firm's stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $61.49, for a total transaction of $1,537,250.00. Following the completion of the sale, the director owned 14,363 shares in the company, valued at $883,180.87. This trade represents a 63.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders sold 100,000 shares of company stock worth $6,271,250. 6.60% of the stock is owned by company insiders.
Institutional Investors Weigh In On PROCEPT BioRobotics
A number of hedge funds have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. grew its position in shares of PROCEPT BioRobotics by 5.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 426,434 shares of the company's stock worth $34,336,000 after acquiring an additional 23,869 shares in the last quarter. Assetmark Inc. acquired a new position in PROCEPT BioRobotics during the 4th quarter worth $667,000. Arizona State Retirement System boosted its position in PROCEPT BioRobotics by 1.5% during the 4th quarter. Arizona State Retirement System now owns 14,285 shares of the company's stock worth $1,150,000 after acquiring an additional 218 shares during the period. Raymond James Financial Inc. acquired a new position in PROCEPT BioRobotics during the 4th quarter worth $1,647,000. Finally, Amundi lifted its holdings in shares of PROCEPT BioRobotics by 0.9% in the fourth quarter. Amundi now owns 20,143 shares of the company's stock valued at $1,742,000 after buying an additional 183 shares during the period. Institutional investors and hedge funds own 89.46% of the company's stock.
About PROCEPT BioRobotics
(
Get Free Report)
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
Recommended Stories

Before you consider PROCEPT BioRobotics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.
While PROCEPT BioRobotics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.